Literature DB >> 1313816

A mechanism generating heterogeneity in thyroid epithelial cells: suppression of the thyrotropin/cAMP-dependent mitogenic pathway after cell division induced by cAMP-independent factors.

P P Roger1, M Baptist, J E Dumont.   

Abstract

The mechanisms that generate the intercellular heterogeneity of functional and proliferation responses in a tissue are generally unknown. In the thyroid gland, this heterogeneity is peculiarly marked and it has been proposed that it could result from the coexistence of genetically different subpopulations of thyrocytes. To evaluate the heterogeneity of proliferative responses in primary culture of dog thyrocytes, we asked whether the progeny of cells having incorporated 3H thymidine in a first period of the culture could have a distinct proliferative fate during a second labeling period (incorporation of bromodeoxyuridine revealed by immunofluorescence staining combined with autoradiography of 3H thymidine). No growth-prone subpopulations were detected and the great majority of cells were found to response to either EGF or thyrotropin (TSH) through cAMP. However, only a fraction of cells replicated DNA at one given period and a clustered distribution of labeled cells within the monolayer, which was different for thymidine- or bromodeoxyuridine-labeled cells, indicates some local and temporal synchrony of neighboring cells. The TSH/cAMP-dependent division of thyrocytes preserved their responsiveness to both TSH and EGF mitogenic pathways. By contrast, cells that had divided during a momentary treatment with EGF lost the mitogenic sensitivity to TSH and cAMP (forskolin) but retained the sensitivity to EGF. Since cells that had not divided kept responsiveness to both TSH and EGF, this generated two subpopulations differing in mitogen responsiveness. The extinction of the TSH/cAMP-dependent mitogenic pathway was delayed (1-2 d) but stable. Cell fusion experiments suggest it was due to the induction of a diffusible intracellular inhibitor of the cAMP-dependent growth pathway. These findings provide a useful model of the generation of a qualitative heterogeneity in the cell sensitivity to various mitogens, which presents analogies with other epigenetic processes, such as differentiation and senescence. They shed a new light on the significance of the coexistence of different modes of cell cycle controls in thyroid epithelial cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313816      PMCID: PMC2289413          DOI: 10.1083/jcb.117.2.383

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  52 in total

1.  Activation and repression of myogenesis in somatic cell hybrids: evidence for trans-negative regulation of MyoD in primary fibroblasts.

Authors:  M J Thayer; H Weintraub
Journal:  Cell       Date:  1990-10-05       Impact factor: 41.582

2.  Intermediate filaments in normal thyrocytes: modulation of vimentin expression in primary cultures.

Authors:  J Coclet; F Lamy; F Rickaert; J E Dumont; P P Roger
Journal:  Mol Cell Endocrinol       Date:  1991-04       Impact factor: 4.102

Review 3.  Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products.

Authors:  A J Levine; J Momand
Journal:  Biochim Biophys Acta       Date:  1990-06-01

4.  Sequence of cell life phases in a finitely proliferative population of cultured rat cells: a genealogical study.

Authors:  T Matsumura
Journal:  J Cell Physiol       Date:  1984-05       Impact factor: 6.384

5.  Loss of division potential in vitro: aging or differentiation?

Authors:  E Bell; L F Marek; D S Levinstone; C Merrill; S Sher; I T Young; M Eden
Journal:  Science       Date:  1978-12-15       Impact factor: 47.728

6.  Cell-cell interactions in the process of differentiation of thyroid epithelial cells into follicles: a study by microinjection and fluorescence microscopy on in vitro reconstituted thyroid follicles.

Authors:  Y Munari-Silem; M Mesnil; S Selmi; F Bernier-Valentin; R Rabilloud; B Rousset
Journal:  J Cell Physiol       Date:  1990-12       Impact factor: 6.384

7.  Differential regulation of protooncogenes c-jun and jun D expressions by protein tyrosine kinase, protein kinase C, and cyclic-AMP mitogenic pathways in dog primary thyrocytes: TSH and cyclic-AMP induce proliferation but downregulate C-jun expression.

Authors:  S Reuse; I Pirson; J E Dumont
Journal:  Exp Cell Res       Date:  1991-10       Impact factor: 3.905

8.  Clonal composition of benign and malignant human thyroid tumors.

Authors:  H Namba; K Matsuo; J A Fagin
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

9.  A cyclic AMP response element mediates repression of tyrosine aminotransferase gene transcription by the tissue-specific extinguisher locus Tse-1.

Authors:  M Boshart; F Weih; A Schmidt; R E Fournier; G Schütz
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

Review 10.  The role of differentiation in the suppression of malignancy.

Authors:  H Harris
Journal:  J Cell Sci       Date:  1990-09       Impact factor: 5.285

View more
  13 in total

1.  Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.

Authors:  Ana Sofia Rocha; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Paula Soares; Pierre P Roger
Journal:  Mol Biol Cell       Date:  2008-09-17       Impact factor: 4.138

Review 2.  Recent insights into the cell biology of thyroid angiofollicular units.

Authors:  Ides M Colin; Jean-François Denef; Benoit Lengelé; Marie-Christine Many; Anne-Catherine Gérard
Journal:  Endocr Rev       Date:  2013-01-24       Impact factor: 19.871

Review 3.  Intrinsic regulation of thyroid function by thyroglobulin.

Authors:  Donald F Sellitti; Koichi Suzuki
Journal:  Thyroid       Date:  2014-01-17       Impact factor: 6.568

4.  Transforming growth factor beta(1) selectively inhibits the cyclic AMP-dependent proliferation of primary thyroid epithelial cells by preventing the association of cyclin D3-cdk4 with nuclear p27(kip1).

Authors:  F Depoortere; I Pirson; J Bartek; J E Dumont; P P Roger
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

5.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Trace Amine-Associated Receptor 1 Localization at the Apical Plasma Membrane Domain of Fisher Rat Thyroid Epithelial Cells Is Confined to Cilia.

Authors:  Joanna Szumska; Maria Qatato; Maren Rehders; Dagmar Führer; Heike Biebermann; David K Grandy; Josef Köhrle; Klaudia Brix
Journal:  Eur Thyroid J       Date:  2015-06-10

7.  Regulation of CDK4.

Authors:  Laurence Bockstaele; Katia Coulonval; Hugues Kooken; Sabine Paternot; Pierre P Roger
Journal:  Cell Div       Date:  2006-11-08       Impact factor: 5.130

8.  A requirement for cyclin D3-cyclin-dependent kinase (cdk)-4 assembly in the cyclic adenosine monophosphate-dependent proliferation of thyrocytes.

Authors:  F Depoortere; A Van Keymeulen; J Lukas; S Costagliola; J Bartkova; J E Dumont; J Bartek; P P Roger; S Dremier
Journal:  J Cell Biol       Date:  1998-03-23       Impact factor: 10.539

9.  Commentary: Thyrotropin Stimulates Differentiation Not Proliferation of Normal Human Thyrocytes in Culture.

Authors:  Aglaia Kyrilli; Sabine Paternot; Françoise Miot; Bernard Corvilain; Gilbert Vassart; Pierre P Roger; Jacques E Dumont
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-25       Impact factor: 5.555

10.  CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Authors:  Eric Raspé; Katia Coulonval; Jaime M Pita; Sabine Paternot; Françoise Rothé; Laure Twyffels; Sylvain Brohée; Ligia Craciun; Denis Larsimont; Véronique Kruys; Flavienne Sandras; Isabelle Salmon; Steven Van Laere; Martine Piccart; Michail Ignatiadis; Christos Sotiriou; Pierre P Roger
Journal:  EMBO Mol Med       Date:  2017-08       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.